Bavarian Nordic begins clinical study of mpox vaccine for children in Africa
manilatimes.net — October 29, 2024, 01:01 PM UTC
Bavarian Nordic has started a clinical study of its MVA-BN mpox vaccine for children aged 2 to 11. This follows recent approvals for adolescents aged 12 to 17 by the European Medicines Agency and the World Health Organization. The study, taking place in the Democratic Republic of Congo and Uganda, aims to enroll 460 participants. It will compare the vaccine's safety and immune response in children to that of adults. Results from this study could lead to expanded approval for the vaccine to include younger children. The MVA-BN vaccine is already approved for use in several countries for individuals aged 12 and older.